Value
8.2/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 7.1 |
| Analyst target | 9.0 |
- ▸Attractively valued
ZLAB · Why this verdict
Why Zai Lab (ZLAB) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Zai Lab operates entirely within mainland China, flagged as a high-concentration geographic risk — a regulatory, intellectual property, or market access deterioration in China directly threatens the entire pipeline and revenue base with no geographic offset. Bear case | Revenue from outside mainland China grows to represent more than 20% of total revenue within 18 months, reducing single-country dependence. | →Stable |
| CounterChina's large and growing pharmaceutical market represents a significant growth opportunity; geographic concentration on China may reflect strategic focus rather than a structural vulnerability at this stage of commercialization. | ||
Analysts target a 63% price gain to $28.97, but Zai Lab has missed earnings estimates in 2 of the last 4 quarters with an average surprise near flat at -0.4%, suggesting that while the pipeline potential is recognized, execution reliability is inconsistent. Targets | EPS surprise rises above 10% in at least 3 of the next 4 quarters, confirming that cash management is improving relative to analyst models. | →Stable |
| CounterAn average surprise near zero in a loss-making biotech indicates that the company is at least meeting the loss expectations analysts model; neither dramatically better nor worse execution than forecast. | ||
Zai Lab burns cash at -16% of revenue with zero positive returns on equity or assets, a Piotroski F-Score of 3/9, and a quality score of 1.6 — far below the minimum 4.0 threshold — indicating a pre-commercial company without durable cash generation capacity. Quality breakdown | Cash burn as a percentage of revenue improves to better than -5% within 12 months, and the Piotroski F-Score rises above 5/9. | →Stable |
| CounterA current ratio of 8.2 suggests Zai Lab has substantial cash reserves to fund its pipeline; the burn rate may be intentional investment in commercialization rather than a structural flaw. | ||
The stock is in a confirmed death-cross breakdown with the 200-day moving average declining at -10.6% per 30 days, placing it below all major moving averages despite MACD improvement and rising on-balance volume. Momentum breakdown | The 200-day moving average slope improves to flat or better within 9 months, and price closes above the 200-day average for at least 10 consecutive days. | →Stable |
| CounterRising on-balance volume alongside a declining price trend can be an early contrarian indicator of accumulation; institutional buyers loading at depressed levels could catalyze a technical reversal. | ||
Zai Lab operates entirely within mainland China, flagged as a high-concentration geographic risk — a regulatory, intellectual property, or market access deterioration in China directly threatens the entire pipeline and revenue base with no geographic offset.
→StableBear case
- Expectation
- Revenue from outside mainland China grows to represent more than 20% of total revenue within 18 months, reducing single-country dependence.
CounterChina's large and growing pharmaceutical market represents a significant growth opportunity; geographic concentration on China may reflect strategic focus rather than a structural vulnerability at this stage of commercialization.
Analysts target a 63% price gain to $28.97, but Zai Lab has missed earnings estimates in 2 of the last 4 quarters with an average surprise near flat at -0.4%, suggesting that while the pipeline potential is recognized, execution reliability is inconsistent.
→StableTargets
- Expectation
- EPS surprise rises above 10% in at least 3 of the next 4 quarters, confirming that cash management is improving relative to analyst models.
CounterAn average surprise near zero in a loss-making biotech indicates that the company is at least meeting the loss expectations analysts model; neither dramatically better nor worse execution than forecast.
Zai Lab burns cash at -16% of revenue with zero positive returns on equity or assets, a Piotroski F-Score of 3/9, and a quality score of 1.6 — far below the minimum 4.0 threshold — indicating a pre-commercial company without durable cash generation capacity.
→StableQuality breakdown
- Expectation
- Cash burn as a percentage of revenue improves to better than -5% within 12 months, and the Piotroski F-Score rises above 5/9.
CounterA current ratio of 8.2 suggests Zai Lab has substantial cash reserves to fund its pipeline; the burn rate may be intentional investment in commercialization rather than a structural flaw.
The stock is in a confirmed death-cross breakdown with the 200-day moving average declining at -10.6% per 30 days, placing it below all major moving averages despite MACD improvement and rising on-balance volume.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope improves to flat or better within 9 months, and price closes above the 200-day average for at least 10 consecutive days.
CounterRising on-balance volume alongside a declining price trend can be an early contrarian indicator of accumulation; institutional buyers loading at depressed levels could catalyze a technical reversal.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Zai Lab is a China-focused biotech with a quality score well below investment thresholds, burning cash at -16% of revenue with no competitive moat and a confirmed death-cross technical breakdown — though analyst consensus implies 63% upside and news sentiment is strongly positive, the execution record is too weak to justify risk-on positioning.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.2 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -16% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
0.9/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.9 |
- ▸Declining revenue: -6%
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.4 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 0.1 |
- ▸Overbought bear rally (RSI 79)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -10.0%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 75%
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $4,188,281 (0.194% of mkt cap)
Peer rank
3.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.7 |
| quality rank | 4.3 |
| growth rank | 3.1 |
Technical
1.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 1.6 |
| 52w position | 0.0 |
Risk (lower is worse)
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.7 |
| days to cover | 2.7 |
| volatility | 2.4 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 8.4 |
| debt equity | 8.6 |
- ▸Elevated put/call: 3.33
- ▸High IV: 137%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 2.8 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.7>=5.5
- ASYMMETRY:3.5>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- DEATH_CROSS:momentum=5.7>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
3.51
Upside
+51.9%
Downside
14.8%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 79
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -57% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.2 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 8.2, Sentiment at 6.6, and Momentum at 5.7; the weakest are Growth at 0.9, Technical at 1.1, and Quality at 1.6. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 3.51 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn Quality Below Threshold
Trip ifCash burn as a percentage of revenue worsens below -25% for 2 consecutive quarters.
- P2China Geographic Concentration
Trip ifA regulatory action in China causes pipeline delays affecting more than 50% of the company's disclosed programs.
- P3Death Cross Steep Downtrend
Trip ifPrice drops below $15, falling more than 15% below the current $17.73, while the 200-day MA slope remains below -8% per 30 days.
- P463pct Analyst Upside Vs Execution
Trip ifAnalyst consensus price target declines below $20, falling more than 30% from the current $28.97.